Annick Desjardins
Professor of Neurosurgery
Current Appointments & Affiliations
- Professor of Neurosurgery, Neurosurgery, Neuro-Oncology, Neurosurgery 2021
- Professor in Neurology, Neurology, General & Community Neurology, Neurology 2021
- Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2003
Contact Information
- Duke Box 3624, Durham, NC 27710
- The Preston Robert Tisch Brain, Rm. 047 Baker House, DUMC 3624, Durham, NC 27710
-
annick.desjardins@duke.edu
(919) 684-5301
- Background
-
Education, Training, & Certifications
- Fellow in Neuro-Oncology, Medicine, Duke University 2003 - 2005
- Resident, Neurology, University of Sherbrooke (Canada) 1998 - 2003
- M.D., University of Sherbrooke (Canada) 1998
-
Medical Licensure
- 2016-00547. North Carolina. 2016
-
Previous Appointments & Affiliations
- Professor in Neurology, Neurology, General & Community Neurology, Neurology 2020 - 2021
- Professor of Neurosurgery, Neurosurgery, Neuro-Oncology, Neurosurgery 2020
- Associate Professor of Neurosurgery, Neurosurgery, Neuro-Oncology, Neurosurgery 2017 - 2020
- Associate Professor in Neurology, Neurology, General & Community Neurology, Neurology 2020
- Associate Professor in Neurology, Neurology, General & Community Neurology, Neurology 2016 - 2020
- Associate Professor in Neurosurgery, Neurosurgery, Neurosurgery 2016 - 2017
- Associate Professor of Neurology, Neurology, General & Community Neurology, Neurology 2013 - 2016
- Assistant Professor of Medicine, Neurology, Clinical Science Departments 2008 - 2013
- Medical Instructor in the Department of Medicine, Neurology, Clinical Science Departments 2005 - 2008
-
Leadership & Clinical Positions at Duke
-
Adult Neuro-Oncologist
Director of Clinical Research, Preston Robert Tisch Brain Tumor Center at Duke
-
Adult Neuro-Oncologist
- Recognition
-
In the News
-
JUN 6, 2016 Duke Today -
JUN 6, 2016 -
MAY 16, 2016 -
JUN 1, 2015 Duke Today -
JUN 1, 2015 -
MAR 31, 2015 Forbes -
MAR 31, 2015 Forbes -
MAR 30, 2015 CBS “60 Minutes” -
MAR 30, 2015 CBS “60 Minutes -
APR 30, 2014 USA Today -
APR 30, 2014 USA Today -
AUG 21, 2013 Al Jazeera America -
AUG 21, 2013 Al Jazeera America -
JUL 19, 2013 ABC News -
JUL 17, 2013 News & Observer
-
- Expertise
-
Global Scholarship
-
Expertise
-
Research
-
- Research
-
Selected Grants
- Phase I open label ascending dose study to assess the feasibility and safety of intermittent infusions of MTX110 administered by convection-enhanced delivery (CED) as a monotherapy or in combination with lomustine in patients with recurrent glioblast awarded by Midatech Pharma Plc 2022 - 2026
- Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer awarded by National Institutes of Health 2014 - 2023
- Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas awarded by National Institutes of Health 2015 - 2022
- Phase 3 randomized, open-label study to evaluate Eflornithine with Lomustine compared to Lomustine (STELLAR) alone in patients with Anaplastic Astrocytoma awarded by Orbus Therapeutics, Inc. 2016 - 2022
- Establishing a Rationale for PVSRIPO Immunotherapy in Newly Diagnosed GBM awarded by National Brain Tumor Society 2019 - 2022
- An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults with Glioblastoma at First Recurrence or Progression awarded by Medicenna Therapeutics, Inc. 2017 - 2022
- Phase 2 study of SYM004 for adult patients with recurrent glioblastoma awarded by Symphogen A/S 2015 - 2021
- Phase 1 Multicenter, Open-Label, Dose-Escalation, Combination Study of Marizomib and Bevacizumab-Naive Subjects with Grade IV Malignant Glioma awarded by Celgene Research and Development 2015 - 2021
- A Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06840003 in Patients with Malignant Glioma awarded by Pfizer, Inc. 2016 - 2020
- Phase 1b, Multicenter, Open-Label Study of Marizomib with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma. MRZ112 awarded by Triphase Research and Development Corp 2016 - 2020
- Development of a Therapeutic for Brain Tumor Immunotherapy awarded by National Institutes of Health 2018 - 2019
- Combining PVSRIPO Immunotherapy with Lomustine for the Treatment of Recurrent GBM awarded by National Brain Tumor Society 2017 - 2019
- A Phase 1 Study of PTC in Patients with Advanced Solid Tumors awarded by PTC Therapeutics, Inc 2016 - 2017
- Phase I/II Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination with Lomustine for Bevacizumab-Niave patients with Recurrent WHO grade IV Malignant Glioma. Study#2 awarded by Tactical Therapeutics, Inc. 2013 - 2016
-
External Relationships
- Istari Oncology
- Midatech Pharma
- Orbus Therapeutics, Inc.
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Shoaf, Madison L., and Annick Desjardins. “Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice.” Neurotherapeutics 19, no. 6 (October 2022): 1818–31. https://doi.org/10.1007/s13311-022-01256-1.Full Text Link to Item
-
Desjardins, Annick. “Improving survival in neuro-oncology is a struggle; we cannot allow ourselves to also struggle with issues of diversity.” Neuro Oncol 24, no. 8 (August 1, 2022): 1350–51. https://doi.org/10.1093/neuonc/noac069.Full Text Link to Item
-
Peters, Katherine B., Mary L. Affronti, Sarah Woodring, Eric Lipp, Patrick Healy, James E. Herndon, Elizabeth S. Miller, et al. “Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial.” Support Care Cancer 30, no. 4 (April 2022): 3463–71. https://doi.org/10.1007/s00520-021-06738-0.Full Text Link to Item
-
Kang, Jennifer H., and Annick Desjardins. “Convection-enhanced delivery for high-grade glioma.” Neurooncol Pract 9, no. 1 (February 2022): 24–34. https://doi.org/10.1093/nop/npab065.Full Text Link to Item
-
Kent, Collin L., Yvonne M. Mowery, Olayode Babatunde, Ato O. Wright, Ian Barak, Frances McSherry, James E. Herndon, et al. “Long-Term Outcomes for Patients With Atypical or Malignant Meningiomas Treated With or Without Radiation Therapy: A 25-Year Retrospective Analysis of a Single-Institution Experience.” Adv Radiat Oncol 7, no. 3 (2022): 100878. https://doi.org/10.1016/j.adro.2021.100878.Full Text Link to Item
-
Kang, Jennifer H., Christa B. Swisher, Evan D. Buckley, James E. Herndon, Eric S. Lipp, John P. Kirkpatrick, Annick Desjardins, et al. “Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis.” Cns Oncol 10, no. 3 (September 1, 2021): CNS77. https://doi.org/10.2217/cns-2021-0009.Full Text Open Access Copy Link to Item
-
Abu Khalaf, N., A. Desjardins, J. J. Vredenburgh, and D. P. Barboriak. “Repeatability of Automated Image Segmentation with BraTumIA in Patients with Recurrent Glioblastoma.” Ajnr Am J Neuroradiol 42, no. 6 (June 2021): 1080–86. https://doi.org/10.3174/ajnr.A7071.Full Text Link to Item
-
Randazzo, Dina M., Frances McSherry, James E. Herndon, Mary L. Affronti, Eric S. Lipp, Elizabeth S. Miller, Sarah Woodring, et al. “Spiritual well-being and its association with health-related quality of life in primary brain tumor patients.” Neurooncol Pract 8, no. 3 (June 2021): 299–309. https://doi.org/10.1093/nop/npaa084.Full Text Link to Item
-
Gromeier, Matthias, Michael C. Brown, Gao Zhang, Xiang Lin, Yeqing Chen, Zhi Wei, Nike Beaubier, et al. “Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.” Nat Commun 12, no. 1 (January 13, 2021): 352. https://doi.org/10.1038/s41467-020-20469-6.Full Text Open Access Copy Link to Item
-
Bota, Daniela A., Warren Mason, Santosh Kesari, Rajiv Magge, Benjamin Winograd, Ileana Elias, Steven D. Reich, Nancy Levin, Mohit Trikha, and Annick Desjardins. “Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data.” Neurooncol Adv 3, no. 1 (2021): vdab142. https://doi.org/10.1093/noajnl/vdab142.Full Text Link to Item
-
Lee, Jessica W., John P. Kirkpatrick, Frances McSherry, James E. Herndon, Eric S. Lipp, Annick Desjardins, Dina M. Randazzo, et al. “Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis.” Front Oncol 11 (2021): 631618. https://doi.org/10.3389/fonc.2021.631618.Full Text Open Access Copy Link to Item
-
Wick, Antje, Annick Desjardins, Cristina Suarez, Peter Forsyth, Ivelina Gueorguieva, Tiana Burkholder, Ann Louise Cleverly, et al. “Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.” Invest New Drugs 38, no. 5 (October 2020): 1570–79. https://doi.org/10.1007/s10637-020-00910-9.Full Text Link to Item
-
Patel, Mallika P., Sarah Woodring, Dina M. Randazzo, Henry S. Friedman, Annick Desjardins, Patrick Healy, James E. Herndon, et al. “Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.” Support Care Cancer 28, no. 5 (May 2020): 2229–38. https://doi.org/10.1007/s00520-019-05039-x.Full Text Link to Item
-
Patel, Mallika P., John P. Kirkpatrick, Margaret O. Johnson, Patrick Healy, James E. Herndon, Eric S. Lipp, Elizabeth S. Miller, et al. “Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.” J Neurooncol 147, no. 2 (April 2020): 477–83. https://doi.org/10.1007/s11060-020-03446-3.Full Text Link to Item
-
Reardon, David A., Annick Desjardins, James J. Vredenburgh, Donald M. O’Rourke, David D. Tran, Karen L. Fink, Louis B. Nabors, et al. “Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.” Clin Cancer Res 26, no. 7 (April 1, 2020): 1586–94. https://doi.org/10.1158/1078-0432.CCR-18-1140.Full Text Link to Item
-
Kim, Jung-Young, Jennifer G. Jackman, Sarah Woodring, Frances McSherry, James E. Herndon, Annick Desjardins, Henry S. Friedman, and Katherine B. Peters. “Second primary cancers in long-term survivors of glioblastoma.” Neurooncol Pract 6, no. 5 (September 2019): 386–91. https://doi.org/10.1093/nop/npz001.Full Text Link to Item
-
Randazzo, Dina M., Frances McSherry, James E. Herndon, Mary L. Affronti, Eric S. Lipp, Charlene Flahiff, Elizabeth Miller, et al. “Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population.” Complement Ther Clin Pract 36 (August 2019): 43–48. https://doi.org/10.1016/j.ctcp.2019.05.002.Full Text Link to Item
-
Chandramohan, Vidyalakshmi, Xuhui Bao, Xin Yu, Scott Parker, Charlotte McDowall, Yen-Rei Yu, Patrick Healy, et al. “Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.” J Immunother Cancer 7, no. 1 (May 29, 2019): 142. https://doi.org/10.1186/s40425-019-0614-0.Full Text Open Access Copy Link to Item
-
Desjardins, Annick, James E. Herndon, Frances McSherry, Arliene Ravelo, Eric S. Lipp, Patrick Healy, Katherine B. Peters, et al. “Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice.” Health Sci Rep 2, no. 4 (April 2019): e114. https://doi.org/10.1002/hsr2.114.Full Text Link to Item
-
Shen, Erica, Margaret O. Johnson, Jessica W. Lee, Eric S. Lipp, Dina M. Randazzo, Annick Desjardins, Roger E. McLendon, et al. “Performance of a nomogram for IDH-wild-type glioblastoma patient survival in an elderly cohort.” Neurooncol Adv 1, no. 1 (2019): vdz036. https://doi.org/10.1093/noajnl/vdz036.Full Text Link to Item
-
Ellingson, Benjamin M., Dana T. Aftab, Gisela M. Schwab, Colin Hessel, Robert J. Harris, Davis C. Woodworth, Kevin Leu, et al. “Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.” Neuro Oncol 20, no. 10 (September 3, 2018): 1411–18. https://doi.org/10.1093/neuonc/noy054.Full Text Link to Item
-
Affronti, Mary Lou, Jennifer Gamboa Jackman, Frances McSherry, James E. Herndon, Elwood C. Massey, Eric Lipp, Annick Desjardins, et al. “Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.” Oncologist 23, no. 8 (August 2018): 889-e98. https://doi.org/10.1634/theoncologist.2018-0149.Full Text Link to Item
-
Desjardins, Annick, Matthias Gromeier, James E. Herndon, Nike Beaubier, Dani P. Bolognesi, Allan H. Friedman, Henry S. Friedman, et al. “Recurrent Glioblastoma Treated with Recombinant Poliovirus.” N Engl J Med 379, no. 2 (July 12, 2018): 150–61. https://doi.org/10.1056/NEJMoa1716435.Full Text Link to Item
-
Keir, Stephen T., Vidyalakshmi Chandramohan, Carlee D. Hemphill, Michael M. Grandal, Maria Carlsen Melander, Mikkel W. Pedersen, Ivan D. Horak, et al. “Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.” J Neurooncol 138, no. 3 (July 2018): 489–98. https://doi.org/10.1007/s11060-018-2832-6.Full Text Open Access Copy Link to Item
-
Peters, Katherine B., Eric S. Lipp, Elizabeth Miller, James E. Herndon, Frances McSherry, Annick Desjardins, David A. Reardon, and Henry S. Friedman. “Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.” J Neurooncol 137, no. 2 (April 2018): 349–56. https://doi.org/10.1007/s11060-017-2724-1.Full Text Link to Item
-
Cloughesy, Timothy F., Jan Drappatz, John de Groot, Michael D. Prados, David A. Reardon, David Schiff, Marc Chamberlain, et al. “Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.” Neuro Oncol 20, no. 2 (January 22, 2018): 259–67. https://doi.org/10.1093/neuonc/nox151.Full Text Link to Item
-
Wen, Patrick Y., Jan Drappatz, John de Groot, Michael D. Prados, David A. Reardon, David Schiff, Marc Chamberlain, et al. “Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.” Neuro Oncol 20, no. 2 (January 22, 2018): 249–58. https://doi.org/10.1093/neuonc/nox154.Full Text Link to Item
-
Dunn-Pirio, Anastasie M., Sarah Woodring, Eric Lipp, James E. Herndon, Patrick Healy, Mallika Weant, Dina Randazzo, Annick Desjardins, Henry S. Friedman, and Katherine B. Peters. “Adjunctive perampanel for glioma-associated epilepsy.” Epilepsy Behav Case Rep 10 (2018): 114–17. https://doi.org/10.1016/j.ebcr.2018.09.003.Full Text Link to Item
-
Reap, Elizabeth A., Carter M. Suryadevara, Kristen A. Batich, Luis Sanchez-Perez, Gary E. Archer, Robert J. Schmittling, Pamela K. Norberg, et al. “Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.” Cancer Res 78, no. 1 (January 1, 2018): 256–64. https://doi.org/10.1158/0008-5472.CAN-17-0469.Full Text Link to Item
-
Weller, Michael, Nicholas Butowski, David D. Tran, Lawrence D. Recht, Michael Lim, Hal Hirte, Lynn Ashby, et al. “Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.” Lancet Oncol 18, no. 10 (October 2017): 1373–85. https://doi.org/10.1016/S1470-2045(17)30517-X.Full Text Link to Item
-
Randazzo, Dina M., Frances McSherry, James E. Herndon, Mary Lou Affronti, Eric S. Lipp, Charlene Flahiff, Elizabeth Miller, et al. “A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population.” J Neurooncol 134, no. 2 (September 2017): 363–69. https://doi.org/10.1007/s11060-017-2535-4.Full Text Link to Item
-
Affronti, Mary Lou, Sarah Woodring, Katherine B. Peters, James E. Herndon, Frances McSherry, Patrick N. Healy, Annick Desjardins, James J. Vredenburgh, and Henry S. Friedman. “A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab.” Ther Clin Risk Manag 13 (2017): 33–40. https://doi.org/10.2147/TCRM.S122480.Full Text Link to Item
-
Desjardins, Annick, Gordana Vlahovic, and Henry S. Friedman. “Vaccine Therapy, Oncolytic Viruses, and Gliomas.” Oncology (Williston Park) 30, no. 3 (March 2016): 211–18.Link to Item
-
Schiff, David, Annick Desjardins, Timothy Cloughesy, Thomas Mikkelsen, Michael Glantz, Marc C. Chamberlain, David A. Reardon, and Patrick Y. Wen. “Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.” Cancer 122, no. 4 (February 15, 2016): 582–87. https://doi.org/10.1002/cncr.29798.Full Text Link to Item
-
Mar, Nataliya, Annick Desjardins, and James J. Vredenburgh. “CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma--The Progress and the Limitations.” Clin Cancer Res 21, no. 19 (October 1, 2015): 4248–50. https://doi.org/10.1158/1078-0432.CCR-15-1381.Full Text Link to Item
-
Robinson, Giles W., Brent A. Orr, Gang Wu, Sridharan Gururangan, Tong Lin, Ibrahim Qaddoumi, Roger J. Packer, et al. “Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.” J Clin Oncol 33, no. 24 (August 20, 2015): 2646–54. https://doi.org/10.1200/JCO.2014.60.1591.Full Text Link to Item
-
Desjardins, Annick. “Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma?” Nat Rev Neurol 11, no. 8 (August 2015): 429–30. https://doi.org/10.1038/nrneurol.2015.127.Full Text Link to Item
-
Peters, Katherine B., Emil Lou, Annick Desjardins, David A. Reardon, Eric S. Lipp, Elizabeth Miller, James E. Herndon, Frances McSherry, Henry S. Friedman, and James J. Vredenburgh. “Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.” Oncologist 20, no. 7 (July 2015): 727–28. https://doi.org/10.1634/theoncologist.2015-0135.Full Text Link to Item
-
Mitchell, Duane A., Elias J. Sayour, Elizabeth Reap, Robert Schmittling, Gabriel DeLeon, Pamela Norberg, Annick Desjardins, et al. “Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.” Cancer Immunol Res 3, no. 4 (April 2015): 320–25. https://doi.org/10.1158/2326-6066.CIR-14-0100.Full Text Link to Item
-
Mitchell, Duane A., Kristen A. Batich, Michael D. Gunn, Min-Nung Huang, Luis Sanchez-Perez, Smita K. Nair, Kendra L. Congdon, et al. “Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.” Nature 519, no. 7543 (March 19, 2015): 366–69. https://doi.org/10.1038/nature14320.Full Text Open Access Copy Link to Item
-
Peters, Katherine B., Miranda J. West, Whitney E. Hornsby, Emily Waner, April D. Coan, Frances McSherry, James E. Herndon, Henry S. Friedman, Annick Desjardins, and Lee W. Jones. “Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients.” J Neurooncol 120, no. 3 (December 2014): 499–506. https://doi.org/10.1007/s11060-014-1574-3.Full Text Link to Item
-
Brown, Michael C., Elena Y. Dobrikova, Mikhail I. Dobrikov, Ross W. Walton, Sarah L. Gemberling, Smita K. Nair, Annick Desjardins, et al. “Oncolytic polio virotherapy of cancer.” Cancer 120, no. 21 (November 1, 2014): 3277–86. https://doi.org/10.1002/cncr.28862.Full Text Link to Item
-
Desjardins, A., J. Herndon, F. McSherry, A. Ravelo, E. Lipp, P. Healy, K. Peters, et al. “AT-20 * SINGLE INSTITUTION RETROSPECTIVE REVIEW OF PERFORMANCE STATUS AND CORTICOSTEROID USE IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS (PTS) TREATED ON BEVACIZUMAB (BEV).” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v12–13. https://doi.org/10.1093/neuonc/nou237.20.Full Text
-
Desjardins, A., J. Herndon, F. McSherry, A. Ravelo, E. Lipp, P. Healy, S. Boulton, et al. “AT-19 * SINGLE INSTITUTION RETROSPECTIVE COMPARISON OF GLIOBLASTOMA (GBM) PATIENTS (PTS) INITIATED ON BEVACIZUMAB (BEV) BEFORE VERSUS AFTER RECURRENCE IN CLINICAL PRACTICE.” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v12–v12. https://doi.org/10.1093/neuonc/nou237.19.Full Text
-
Desjardins, A., J. Sampson, K. Peters, G. Vlahovic, S. Threatt, J. Herndon, S. Boulton, et al. “AT-21 * FINAL RESULTS OF A PHASE 1 TRIAL OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) AGAINST RECURRENT GLIOBLASTOMA (GBM).” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v13–v13. https://doi.org/10.1093/neuonc/nou237.21.Full Text
-
Ghiaseddin, A., A. Dunn-Pirio, K. Peters, G. Vlahovic, J. Herndon, S. Threatt, J. Sampson, A. Friedman, H. Friedman, and A. Desjardins. “AT-22 * PHASE II TRIAL OF BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION.” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v13–v13. https://doi.org/10.1093/neuonc/nou237.22.Full Text
-
Kang, J., A. Desjardins, P. Healy, J. Herndon, E. Lipp, K. Peters, G. Vlahovic, et al. “SM-02 * LEVETIRACETAM USAGE IN POST-OPERATIVE SEIZURE MANAGEMENT IN MALIGNANT GLIOMA.” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v206–v206. https://doi.org/10.1093/neuonc/nou277.2.Full Text
-
Mowery, Y., A. Wright, A. Desjardins, K. Peters, T. Ranjan, G. Vlahovic, H. Friedman, et al. “MS-19 * LONG-TERM OUTCOMES FOR PATIENTS WITH INTRACRANIAL MENINGIOMAS: A SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS.” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v130–31. https://doi.org/10.1093/neuonc/nou260.18.Full Text
-
Ranjan, T., K. B. Peters, G. Vlahovic, J. Watts, S. Dutton, S. Boulton, E. Lipp, et al. “AT-48 * A PHASE 1 TRIAL OF CARBOXYAMIDOTRIAZOLE OROTATE (CTO) IN COMBINATION WITH BEVACIZUMAB FOR ADULT PATIENTS WITH RECURRENT MALIGNANT GLIOMA POST-BEVACIZUMAB FAILURE.” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v19–v19. https://doi.org/10.1093/neuonc/nou237.47.Full Text
-
Reardon, D., J. Schuster, D. Tran, K. Fink, L. Nabors, G. Li, R. Lukas, et al. “IT-30 * ReACT: A PHASE II STUDY OF RINDOPEPIMUT VACCINE (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA.” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v116–v116. https://doi.org/10.1093/neuonc/nou258.28.Full Text
-
Vlahovic, G., G. Archer, D. Lally-Goss, E. Reap, K. Batich, A. Desjardins, K. Peters, et al. “IT-34 * PILOT STUDY OF COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM).” Neuro Oncology 16, no. suppl 5 (November 1, 2014): v117–v117. https://doi.org/10.1093/neuonc/nou258.32.Full Text
-
Desjardins, A., J. H. Sampson, K. B. Peters, T. Ranjan, G. Vlahovic, S. Threatt, J. E. Herndon, et al. “Oncolytic polio/rhinovirus recombinant (pvsripo) in recurrent glioblastoma (gbm): first phase I clinical trial evaluating the intratumoral administration.” Neuro Oncol 16 Suppl 3 (July 2014): iii43. https://doi.org/10.1093/neuonc/nou209.5.Full Text Link to Item
-
Gromeier, M., E. Dobrikova, M. Dobrikov, M. Brown, J. Bryant, S. Threatt, S. Boulton, et al. “Oncolytic poliovirus immunotherapy of glioblastoma.” Neuro Oncol 16 Suppl 3 (July 2014): iii41. https://doi.org/10.1093/neuonc/nou208.69.Full Text Link to Item
-
Desjardins, Annick, and Henry S. Friedman. “Bevacizumab therapy for glioblastoma: a passionate discussion.” Cns Oncol 3, no. 1 (January 2014): 1–3. https://doi.org/10.2217/cns.13.53.Full Text Link to Item
-
Mazurowski, Maciej Andrzej, Annick Desjardins, and Jordan Milton Malof. “Imaging descriptors improve the predictive power of survival models for glioblastoma patients.” Neuro Oncol 15, no. 10 (October 2013): 1389–94. https://doi.org/10.1093/neuonc/nos335.Full Text Link to Item
-
Cabrera, Alvin R., Kyle C. Cuneo, Annick Desjardins, John H. Sampson, Frances McSherry, James E. Herndon, Katherine B. Peters, et al. “Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.” Int J Radiat Oncol Biol Phys 86, no. 5 (August 1, 2013): 873–79. https://doi.org/10.1016/j.ijrobp.2013.04.029.Full Text Link to Item
-
Jiang, Xiaoyin, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Jennifer A. Quinn, Alan D. Austin, James E. Herndon, Roger E. McLendon, and Henry S. Friedman. “O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.” J Neurooncol 114, no. 1 (August 2013): 135–40. https://doi.org/10.1007/s11060-013-1162-y.Full Text Link to Item
-
Lou, Emil, Katherine B. Peters, Ashley L. Sumrall, Annick Desjardins, David A. Reardon, Eric S. Lipp, James E. Herndon, et al. “Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.” Cancer Med 2, no. 2 (April 2013): 185–95. https://doi.org/10.1002/cam4.58.Full Text Open Access Copy Link to Item
-
Reardon, D. A., J. E. Herndon, K. B. Peters, A. Desjardins, A. Coan, E. Lou, A. L. Sumrall, et al. “Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.” Br J Cancer 107, no. 9 (October 23, 2012): 1481–87. https://doi.org/10.1038/bjc.2012.415.Full Text Open Access Copy Link to Item
-
Reardon, David A., Annick Desjardins, James J. Vredenburgh, James E. Herndon, April Coan, Sridharan Gururangan, Katherine B. Peters, et al. “Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.” Cancer 118, no. 19 (October 1, 2012): 4759–67. https://doi.org/10.1002/cncr.26541.Full Text Link to Item
-
Lou, Emil, Ashley L. Sumrall, Scott Turner, Katherine B. Peters, Annick Desjardins, James J. Vredenburgh, Roger E. McLendon, et al. “Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.” J Neurooncol 109, no. 1 (August 2012): 63–70. https://doi.org/10.1007/s11060-012-0861-0.Full Text Link to Item
-
Friedman, H. S., and A. Desjardins. “Adjuvant PCV chemo hikes oligodendroglioma survival: Commentary.” Oncology Report, no. JULY (July 1, 2012): 6.
-
Reardon, David A., James J. Vredenburgh, Annick Desjardins, Katherine B. Peters, Sith Sathornsumetee, Stevie Threatt, John H. Sampson, et al. “Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.” J Neurooncol 108, no. 3 (July 2012): 499–506. https://doi.org/10.1007/s11060-012-0848-x.Full Text Link to Item
-
Cuneo, Kyle C., James J. Vredenburgh, John H. Sampson, David A. Reardon, Annick Desjardins, Katherine B. Peters, Henry S. Friedman, Christopher G. Willett, and John P. Kirkpatrick. “Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.” Int J Radiat Oncol Biol Phys 82, no. 5 (April 1, 2012): 2018–24. https://doi.org/10.1016/j.ijrobp.2010.12.074.Full Text Link to Item
-
Mason, Warren P., Karl Belanger, Garth Nicholas, Isabelle Vallières, David Mathieu, Petr Kavan, Annick Desjardins, Antonio Omuro, and Didier Reymond. “A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression.” J Neurooncol 107, no. 2 (April 2012): 343–49. https://doi.org/10.1007/s11060-011-0747-6.Full Text Link to Item
-
Paldino, M. J., A. Desjardins, H. S. Friedman, J. J. Vredenburgh, and D. P. Barboriak. “A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme.” Br J Radiol 85, no. 1012 (April 2012): 382–89. https://doi.org/10.1259/bjr/24774491.Full Text Link to Item
-
Desjardins, Annick, and Henry S. Friedman. “Neuro-oncology: Glioblastoma--community adjusts to new standard of care.” Nat Rev Neurol 8, no. 5 (March 20, 2012): 244–46. https://doi.org/10.1038/nrneurol.2012.42.Full Text Link to Item
-
Desjardins, Annick, David A. Reardon, April Coan, Jennifer Marcello, James E. Herndon, Leighann Bailey, Katherine B. Peters, Henry S. Friedman, and James J. Vredenburgh. “Bevacizumab and daily temozolomide for recurrent glioblastoma.” Cancer 118, no. 5 (March 1, 2012): 1302–12. https://doi.org/10.1002/cncr.26381.Full Text Link to Item
-
Reardon, David A., Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon, et al. “Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.” J Neurooncol 107, no. 1 (March 2012): 155–64. https://doi.org/10.1007/s11060-011-0722-2.Full Text Link to Item
-
Reardon, David A., James E. Herndon, Katherine Peters, Annick Desjardins, April Coan, Emil Lou, Ashley Sumrall, et al. “Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.” J Neurooncol 107, no. 1 (March 2012): 213–21. https://doi.org/10.1007/s11060-011-0740-0.Full Text Link to Item
-
Desjardins, Annick, and John H. Sampson. “Avastin: more questions than answers. .” J Neurosurg 116, no. 2 (February 2012): 336–40. https://doi.org/10.3171/2011.8.JNS111107.Full Text Link to Item
-
Reardon, David A., Andrew D. Norden, Annick Desjardins, James J. Vredenburgh, James E. Herndon, April Coan, John H. Sampson, et al. “Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.” J Neurooncol 106, no. 2 (January 2012): 409–15. https://doi.org/10.1007/s11060-011-0687-1.Full Text Link to Item
-
Sampson, John H., Robert J. Schmittling, Gary E. Archer, Kendra L. Congdon, Smita K. Nair, Elizabeth A. Reap, Annick Desjardins, et al. “A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.” Plos One 7, no. 2 (2012): e31046. https://doi.org/10.1371/journal.pone.0031046.Full Text Open Access Copy Link to Item
-
Vredenburgh, James J., Annick Desjardins, John P. Kirkpatrick, David A. Reardon, Katherine B. Peters, James E. Herndon, Jennifer Marcello, et al. “Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.” Int J Radiat Oncol Biol Phys 82, no. 1 (January 1, 2012): 58–66. https://doi.org/10.1016/j.ijrobp.2010.08.058.Full Text Link to Item
-
Desjardins, Annick, David A. Reardon, Katherine B. Peters, Stevie Threatt, April D. Coan, James E. Herndon, Allan H. Friedman, Henry S. Friedman, and James J. Vredenburgh. “A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.” J Neurooncol 105, no. 3 (December 2011): 601–6. https://doi.org/10.1007/s11060-011-0627-0.Full Text Link to Item
-
Reardon, David A., Annick Desjardins, Katherine B. Peters, James J. Vredenburgh, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, et al. “Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.” Cancer 117, no. 23 (December 1, 2011): 5351–58. https://doi.org/10.1002/cncr.26188.Full Text Link to Item
-
Reardon, David A., James J. Vredenburgh, April Coan, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, Sith Sathornsumetee, Jeremy N. Rich, James E. Herndon, and Henry S. Friedman. “Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.” J Neurooncol 105, no. 3 (December 2011): 621–27. https://doi.org/10.1007/s11060-011-0631-4.Full Text Link to Item
-
Lou, Emil, Scott Turner, Ashley Sumrall, David A. Reardon, Annick Desjardins, Katherine B. Peters, John H. Sampson, Henry S. Friedman, and James J. Vredenburgh. “Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.” J Clin Oncol 29, no. 28 (October 1, 2011): e739–42. https://doi.org/10.1200/JCO.2011.36.1865.Full Text Link to Item
-
Turner, Scott G., Katherine B. Peters, James J. Vredenburgh, Annick Desjardins, Henry S. Friedman, and David A. Reardon. “Everolimus tablets for patients with subependymal giant cell astrocytoma.” Expert Opin Pharmacother 12, no. 14 (October 2011): 2265–69. https://doi.org/10.1517/14656566.2011.601742.Full Text Link to Item
-
Mitchell, Duane A., Xiuyu Cui, Robert J. Schmittling, Luis Sanchez-Perez, David J. Snyder, Kendra L. Congdon, Gary E. Archer, et al. “Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.” Blood 118, no. 11 (September 15, 2011): 3003–12. https://doi.org/10.1182/blood-2011-02-334565.Full Text Link to Item
-
Ruden, Emily, David A. Reardon, April D. Coan, James E. Herndon, Whitney E. Hornsby, Miranda West, Diane R. Fels, et al. “Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.” J Clin Oncol 29, no. 21 (July 20, 2011): 2918–23. https://doi.org/10.1200/JCO.2011.34.9852.Full Text Link to Item
-
Vredenburgh, James J., Annick Desjardins, David A. Reardon, Katherine B. Peters, James E. Herndon, Jennifer Marcello, John P. Kirkpatrick, et al. “The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.” Clin Cancer Res 17, no. 12 (June 15, 2011): 4119–24. https://doi.org/10.1158/1078-0432.CCR-11-0120.Full Text Link to Item
-
Reardon, David A., Annick Desjardins, Katherine Peters, Sridharan Gururangan, John Sampson, Jeremy N. Rich, Roger McLendon, et al. “Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.” J Neurooncol 103, no. 2 (June 2011): 371–79. https://doi.org/10.1007/s11060-010-0403-6.Full Text Link to Item
-
Reardon, David A., Scott Turner, Katherine B. Peters, Annick Desjardins, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, et al. “A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.” J Natl Compr Canc Netw 9, no. 4 (April 2011): 414–27. https://doi.org/10.6004/jnccn.2011.0038.Full Text Link to Item
-
Sampson, John H., Kenneth D. Aldape, Gary E. Archer, April Coan, Annick Desjardins, Allan H. Friedman, Henry S. Friedman, et al. “Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.” Neuro Oncol 13, no. 3 (March 2011): 324–33. https://doi.org/10.1093/neuonc/noq157.Full Text Link to Item
-
Kanaly, Charles W., Dale Ding, Ankit I. Mehta, Anthony F. Waller, Ian Crocker, Annick Desjardins, David A. Reardon, Allan H. Friedman, Darell D. Bigner, and John H. Sampson. “A novel method for volumetric MRI response assessment of enhancing brain tumors.” Plos One 6, no. 1 (January 26, 2011): e16031. https://doi.org/10.1371/journal.pone.0016031.Full Text Link to Item
-
Foo, W. -. C., A. Desjardins, and T. J. Cummings. “Primary intracerebral Hodgkin lymphoma with recurrence.” Clin Neuropathol 30, no. 2 (2011): 75–79. https://doi.org/10.5414/npp30075.Full Text Link to Item
-
Peters, Katherine B., Thomas E. Coyle, James J. Vredenburgh, Annick Desjardins, Henry S. Friedman, and David A. Reardon. “Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy.” J Neurooncol 101, no. 1 (January 2011): 155–59. https://doi.org/10.1007/s11060-010-0239-0.Full Text Link to Item
-
Reardon, David A., James J. Vredenburgh, Annick Desjardins, Katherine Peters, Sridharan Gururangan, John H. Sampson, Jennifer Marcello, et al. “Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.” J Neurooncol 101, no. 1 (January 2011): 57–66. https://doi.org/10.1007/s11060-010-0217-6.Full Text Link to Item
-
Sathornsumetee, Sith, Annick Desjardins, James J. Vredenburgh, Roger E. McLendon, Jennifer Marcello, James E. Herndon, Alyssa Mathe, et al. “Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.” Neuro Oncol 12, no. 12 (December 2010): 1300–1310. https://doi.org/10.1093/neuonc/noq099.Full Text Link to Item
-
Aliabadi, Hamidreza, James J. Vredenburgh, Richard G. Everson, Annick Desjardins, Henry S. Friedman, Roger E. McLendon, Debara L. Tucci, and John H. Sampson. “Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration.” J Neurooncol 98, no. 3 (July 2010): 427–30. https://doi.org/10.1007/s11060-009-0091-2.Full Text Link to Item
-
Reardon, David A., Annick Desjardins, James J. Vredenburgh, Sridharan Gururangan, Allan H. Friedman, James E. Herndon, Jennifer Marcello, et al. “Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.” J Neurooncol 96, no. 2 (January 2010): 219–30. https://doi.org/10.1007/s11060-009-9950-0.Full Text Link to Item
-
Reardon, D. A., A. Desjardins, J. J. Vredenburgh, S. Gururangan, J. H. Sampson, S. Sathornsumetee, R. E. McLendon, et al. “Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.” Br J Cancer 101, no. 12 (December 15, 2009): 1986–94. https://doi.org/10.1038/sj.bjc.6605412.Full Text Open Access Copy Link to Item
-
Quinn, Jennifer A., Sara Xiaoyin Jiang, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Allan H. Friedman, John H. Sampson, Roger E. McLendon, James E. Herndon, and Henry S. Friedman. “Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.” J Neurooncol 95, no. 3 (December 2009): 393–400. https://doi.org/10.1007/s11060-009-9937-x.Full Text Link to Item
-
Perry, Stephanie L., Cindy Bohlin, David A. Reardon, Annick Desjardins, Allan H. Friedman, Henry S. Friedman, and James J. Vredenburgh. “Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients.” J Neurooncol 95, no. 1 (October 2009): 129–34. https://doi.org/10.1007/s11060-009-9911-7.Full Text Link to Item
-
Quinn, Jennifer A., Sara Xiaoyin Jiang, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Jeremy N. Rich, Sridharan Gururangan, et al. “Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.” Neuro Oncol 11, no. 5 (October 2009): 556–61. https://doi.org/10.1215/15228517-2009-007.Full Text Link to Item
-
Affronti, Mary Lou, Christopher R. Heery, James E. Herndon, Jeremy N. Rich, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Allan H. Friedman, Darell D. Bigner, and Henry S. Friedman. “Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.” Cancer 115, no. 15 (August 1, 2009): 3501–11. https://doi.org/10.1002/cncr.24398.Full Text Link to Item
-
Jones, Lee W., Rachel-Rose Cohen, Stephanie K. Mabe, Miranda J. West, Annick Desjardins, James J. Vredenburgh, Allan H. Friedman, David A. Reardon, Emily Waner, and Henry S. Friedman. “Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing.” J Neurooncol 94, no. 1 (August 2009): 79–85. https://doi.org/10.1007/s11060-009-9803-x.Full Text Link to Item
-
Quinn, Jennifer A., Sara Xiaoyin Jiang, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon, and Henry S. Friedman. “Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.” Cancer 115, no. 13 (July 1, 2009): 2964–70. https://doi.org/10.1002/cncr.24336.Full Text Link to Item
-
Reardon, David A., Merrill J. Egorin, Annick Desjardins, James J. Vredenburgh, Jan H. Beumer, Theodore F. Lagattuta, Sridharan Gururangan, James E. Herndon, August J. Salvado, and Henry S. Friedman. “Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.” Cancer 115, no. 10 (May 15, 2009): 2188–98. https://doi.org/10.1002/cncr.24213.Full Text Link to Item
-
Paldino, Michael J., Daniel Barboriak, Annick Desjardins, Henry S. Friedman, and James J. Vredenburgh. “Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme.” J Magn Reson Imaging 29, no. 5 (May 2009): 1199–1205. https://doi.org/10.1002/jmri.21732.Full Text Link to Item
-
Reardon, David A., Sith Sathornsumetee, James J. Vredenburgh, Jeremy N. Rich, Annick Desjardins, Jennifer A. Quinn, Alyssa Mathe, Sridharan Gururangan, Allen H. Friedman, and Henry S. Friedman. “PHASE II STUDY OF BEVACIZUMAB AND ERLOTINIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME.” Neuro Oncology 11, no. 2 (April 1, 2009): 231–231.Link to Item
-
Quinn, Jennifer A., Sara Xiaoyin Jiang, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Jeremy N. Rich, Sridharan Gururangan, et al. “Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.” J Clin Oncol 27, no. 8 (March 10, 2009): 1262–67. https://doi.org/10.1200/JCO.2008.18.8417.Full Text Link to Item
-
Quinn, Jennifer A., Sara Xiaoyin Jiang, James Carter, David A. Reardon, Annick Desjardins, James J. Vredenburgh, Jeremy N. Rich, et al. “Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.” Clin Cancer Res 15, no. 3 (February 1, 2009): 1064–68. https://doi.org/10.1158/1078-0432.CCR-08-2130.Full Text Link to Item
-
Vredenburgh, James J., Annick Desjardins, David A. Reardon, and Henry S. Friedman. “Experience with irinotecan for the treatment of malignant glioma.” Neuro Oncol 11, no. 1 (February 2009): 80–91. https://doi.org/10.1215/15228517-2008-075.Full Text Link to Item
-
Desjardins, Annick, David A. Reardon, and James J. Vredenburgh. “Current available therapies and future directions in the treatment of malignant gliomas.” Biologics 3 (2009): 15–25.Link to Item
-
Vredenburgh, J. J., J. N. Rich, D. A. Reardon, A. Desjardins, and H. S. Friedman. “In reply.” Journal of Clinical Oncology 26, no. 32 (November 10, 2008): 5305. https://doi.org/10.1200/JCO.2008.18.0372.Full Text
-
Desjardins, Annick, David A. Reardon, James E. Herndon, Jennifer Marcello, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, et al. “Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.” Clin Cancer Res 14, no. 21 (November 1, 2008): 7068–73. https://doi.org/10.1158/1078-0432.CCR-08-0260.Full Text Link to Item
-
Gururangan, Sridharan, Jeanne Krauser, Melody A. Watral, Tim Driscoll, Nicole Larrier, David A. Reardon, Jeremy N. Rich, et al. “Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma.” Neuro Oncol 10, no. 5 (October 2008): 745–51. https://doi.org/10.1215/15228517-2008-044.Full Text Link to Item
-
Reardon, David A., Annick Desjardins, James J. Vredenburgh, Sith Sathornsumetee, Jeremy N. Rich, Jennifer A. Quinn, Theodore F. Lagattuta, et al. “Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.” Neuro Oncol 10, no. 3 (June 2008): 330–40. https://doi.org/10.1215/15228517-2008-003.Full Text Link to Item
-
Everson, Richard G., Michael W. Graner, Matthias Gromeier, James J. Vredenburgh, Annick Desjardins, David A. Reardon, Henry S. Friedman, Allan H. Friedman, Darell D. Bigner, and John H. Sampson. “Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.” Expert Rev Anticancer Ther 8, no. 5 (May 2008): 717–32. https://doi.org/10.1586/14737140.8.5.717.Full Text Link to Item
-
Reardon, David A., Michael R. Zalutsky, Gamal Akabani, R Edward Coleman, Allan H. Friedman, James E. Herndon, Roger E. McLendon, et al. “A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.” Neuro Oncol 10, no. 2 (April 2008): 182–89. https://doi.org/10.1215/15228517-2007-053.Full Text Link to Item
-
Reardon, David A., Patrick Y. Wen, Annick Desjardins, Tracy T. Batchelor, and James J. Vredenburgh. “Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.” Expert Opin Biol Ther 8, no. 4 (April 2008): 541–53. https://doi.org/10.1517/14712598.8.4.541.Full Text Link to Item
-
Vredenburgh, J., A. Desjardins, and D. Reardon. “Irinotecan and bevacizumab for the treatment of recurrent glioblastoma multiforme.” American Journal of Hematology/ Oncology 7, no. 4 (April 1, 2008).
-
Vredenburgh, J. J., A. Desjardins, D. A. Reardon, and H. S. Friedman. “In reply.” Journal of Clinical Oncology 26, no. 6 (February 20, 2008): 1013. https://doi.org/10.1200/JCO.2007.15.1746.Full Text
-
Reardon, David A., Annick Desjardins, Jeremy N. Rich, and James J. Vredenburgh. “The emerging role of anti-angiogenic therapy for malignant glioma.” Curr Treat Options Oncol 9, no. 1 (February 2008): 1–22. https://doi.org/10.1007/s11864-008-0052-6.Full Text Link to Item
-
Sathornsumetee, Sith, Yiting Cao, Jennifer E. Marcello, James E. Herndon, Roger E. McLendon, Annick Desjardins, Henry S. Friedman, Mark W. Dewhirst, James J. Vredenburgh, and Jeremy N. Rich. “Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.” J Clin Oncol 26, no. 2 (January 10, 2008): 271–78. https://doi.org/10.1200/JCO.2007.13.3652.Full Text Link to Item
-
Guiu, S., S. Taillibert, O. Chinot, L. Taillandier, J. Honnorat, P. Y. Dietrich, J. -. P. Maire, et al. “[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].” Rev Neurol (Paris) 164, no. 6–7 (2008): 588–94. https://doi.org/10.1016/j.neurol.2008.04.003.Full Text Link to Item
-
Vredenburgh, James J., Annick Desjardins, James E. Herndon, Jennifer Marcello, David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, et al. “Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.” J Clin Oncol 25, no. 30 (October 20, 2007): 4722–29. https://doi.org/10.1200/JCO.2007.12.2440.Full Text Link to Item
-
Bota, Daniela A., Annick Desjardins, Jennifer A. Quinn, Mary L. Affronti, and Henry S. Friedman. “Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas.” Ther Clin Risk Manag 3, no. 5 (October 2007): 707–15.Link to Item
-
Sathornsumetee, Sith, David A. Reardon, Annick Desjardins, Jennifer A. Quinn, James J. Vredenburgh, and Jeremy N. Rich. “Molecularly targeted therapy for malignant glioma.” Cancer 110, no. 1 (July 1, 2007): 13–24. https://doi.org/10.1002/cncr.22741.Full Text Link to Item
-
Desjardins, Annick, Jennifer A. Quinn, James J. Vredenburgh, Sith Sathornsumetee, Allan H. Friedman, James E. Herndon, Roger E. McLendon, et al. “Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.” J Neurooncol 83, no. 1 (May 2007): 53–60. https://doi.org/10.1007/s11060-006-9302-2.Full Text Link to Item
-
Gururangan, Sridharan, Michael J. Fisher, Jeffrey C. Allen, James E. Herndon, Jennifer A. Quinn, David A. Reardon, James J. Vredenburgh, et al. “Temozolomide in children with progressive low-grade glioma.” Neuro Oncol 9, no. 2 (April 2007): 161–68. https://doi.org/10.1215/15228517-2006-030.Full Text Link to Item
-
Sathornsumetee, S., A. DesJardins, D. A. Reardon, J. N. Rich, and J. J. Vredenburgh. “Neurofibromatosis type 2.” Neurology 68, no. 13 (March 27, 2007): E14. https://doi.org/10.1212/01.wnl.0000257828.56178.9f.Full Text Link to Item
-
Vredenburgh, James J., Annick Desjardins, James E. Herndon, Jeannette M. Dowell, David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, et al. “Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.” Clin Cancer Res 13, no. 4 (February 15, 2007): 1253–59. https://doi.org/10.1158/1078-0432.CCR-06-2309.Full Text Link to Item
-
Badruddoja, Michael A., Kara Penne, Annick Desjardins, David A. Reardon, Jeremy N. Rich, Jennifer A. Quinn, Sith Sathornsumetee, et al. “Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.” Neuro Oncol 9, no. 1 (January 2007): 70–74. https://doi.org/10.1215/15228517-2006-022.Full Text Link to Item
-
Reardon, David A., Jennifer A. Quinn, Gamal Akabani, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, et al. “Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.” J Nucl Med 47, no. 6 (June 2006): 912–18.Link to Item
-
Reardon, David A., Jennifer A. Quinn, James J. Vredenburgh, Sridharan Gururangan, Allan H. Friedman, Annick Desjardins, Sith Sathornsumetee, et al. “Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.” Clin Cancer Res 12, no. 3 Pt 1 (February 1, 2006): 860–68. https://doi.org/10.1158/1078-0432.CCR-05-2215.Full Text Link to Item
-
Reardon, David A., Gamal Akabani, R Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, Roger E. McLendon, et al. “Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.” J Clin Oncol 24, no. 1 (January 1, 2006): 115–22. https://doi.org/10.1200/JCO.2005.03.4082.Full Text Link to Item
-
Reardon, David A., Merrill J. Egorin, Jennifer A. Quinn, Jeremy N. Rich, Sridharan Gururangan, James J. Vredenburgh, Annick Desjardins, et al. “Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.” J Clin Oncol 23, no. 36 (December 20, 2005): 9359–68. https://doi.org/10.1200/JCO.2005.03.2185.Full Text Link to Item
-
Quinn, Jennifer A., Annick Desjardins, Jon Weingart, Henry Brem, M Eileen Dolan, Shannon M. Delaney, James Vredenburgh, et al. “Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.” J Clin Oncol 23, no. 28 (October 1, 2005): 7178–87. https://doi.org/10.1200/JCO.2005.06.502.Full Text Link to Item
-
Reardon, David A., Jennifer A. Quinn, Jeremy N. Rich, Annick Desjardins, James Vredenburgh, Sridharan Gururangan, Sith Sathornsumetee, et al. “Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.” Cancer 104, no. 7 (October 1, 2005): 1478–86. https://doi.org/10.1002/cncr.21316.Full Text Link to Item
-
Desjardins, Annick, Jeremy N. Rich, Jennifer A. Quinn, James Vredenburgh, Sridharan Gururangan, Sith Sathornsumetee, David A. Reardon, Allan H. Friedman, Darell D. Bigner, and Henry S. Friedman. “Chemotherapy and novel therapeutic approaches in malignant glioma.” Front Biosci 10 (September 1, 2005): 2645–68. https://doi.org/10.2741/1727.Full Text Link to Item
-
Fortin, David, Annick Desjardins, Andrew Benko, Theophylle Niyonsega, and Marie Boudrias. “Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.” Cancer 103, no. 12 (June 15, 2005): 2606–15. https://doi.org/10.1002/cncr.21112.Full Text Link to Item
-
Fortin, David, Joseph A. Salamé, Annick Desjardins, and Andrew Benko. “Technical modification in the intracarotid chemotherapy and osmotic blood-brain barrier disruption procedure to prevent the relapse of carboplatin-induced orbital pseudotumor.” Ajnr Am J Neuroradiol 25, no. 5 (May 2004): 830–34.Link to Item
-
-
Book Sections
-
Desjardins, A. “Bevacizumab and Brain Tumors.” In Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy: Second Edition, 373–81, 2018. https://doi.org/10.1016/B978-0-12-812100-9.00028-0.Full Text
-
Desjardins, A., and H. S. Friedman. “Chemotherapy for gliomas.” In The Duke Glioma Handbook: Pathology, Diagnosis, and Management, 76–90, 2016. https://doi.org/10.1017/CBO9781107588721.005.Full Text
-
-
Journal Issues
-
Ghiaseddin, Ashley, David Reardon, Woody Massey, Alex Mannerino, Eric S. Lipp, James E. Herndon, Frances McSherry, et al. “Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.” Oncologist, February 2018. https://doi.org/10.1634/theoncologist.2017-0501.Full Text Link to Item
-
-
Conference Papers
-
Reardon, David A., Annick Desjardins, Olivier Rixe, Timothy Cloughesy, Shilpa Alekar, Jason H. Williams, Ray Li, Carrie Turich Taylor, and Andrew B. Lassman. “A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma.” In Invest New Drugs, 38:1784–95, 2020. https://doi.org/10.1007/s10637-020-00950-1.Full Text Link to Item
-
Affronti, Mary Lou, Sarah Woodring, Karen Allen, John Kirkpatrick, Katherine B. Peters, James E. Herndon, Frances McSherry, et al. “Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).” In Support Care Cancer, 24:4365–75, 2016. https://doi.org/10.1007/s00520-016-3276-1.Full Text Link to Item
-
Di, Kaijun, G Kenneth Lloyd, Vivek Abraham, Ann MacLaren, Francis J. Burrows, Annick Desjardins, Mohit Trikha, and Daniela A. Bota. “Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.” In Neuro Oncol, 18:840–48, 2016. https://doi.org/10.1093/neuonc/nov299.Full Text Link to Item
-
Peters, K., D. Randazzo, M. Affronti, E. Lipp, F. McSherry, J. Herndon, C. Flahiff, et al. “QL-20 PROGNOSTIC IMPORTANCE OF HEALTH-RELATED QUALITY OF LIFE AND FATIGUE IN NEWLY DIAGNOSED GLIOBLASTOMA.” In Neuro Oncology, 16:v182–v182. Oxford University Press (OUP), 2014. https://doi.org/10.1093/neuonc/nou269.19.Full Text Link to Item
-
Peters, K., D. Reardon, D. Randazzo, S. Dutton, A. Edwards, E. Lipp, J. Herndon, et al. “AT-46 VORINOSTAT AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMA: INTERIM ANALYSIS OF A PHASE II CLINICAL TRIAL.” In Neuro Oncology, 16:v18–v18. Oxford University Press (OUP), 2014. https://doi.org/10.1093/neuonc/nou237.45.Full Text Link to Item
-
Randazzo, D., M. Affronti, E. Lipp, F. McSherry, J. Herndon, C. Flahiff, E. Miller, et al. “QL-21 SPIRITUAL WELL-BEING AND ITS ASSOCIATION WITH HEALTH-RELATED QUALITY OF LIFE IN PRIMARY BRAIN TUMOR PATIENTS.” In Neuro Oncology, 16:v182–83. Oxford University Press (OUP), 2014. https://doi.org/10.1093/neuonc/nou269.20.Full Text Link to Item
-
-
- Scholarly, Clinical, & Service Activities
-
Presentations & Appearances
- “Standardization of Response Criteria for Oncolytic Viral Therapy Working Group”. LIVE EVENT- 2022 RANO/SNO Virtual Meeting. January 28, 2022 - January 28, 2022 2022
- “Oncolytic Virotherapy”. SIG Series 2021: Neuro-Oncology session. American Neurological Association 2021 Virtual Annual Meeting. December 17, 2021 - December 17, 2021 2021
- “How Poliovirus Became a Treatment for Brain Cancer”. Institute for Translational Medicine and Therapeutics, 15th Annual International Symposium. October 12, 2020 - October 13, 2020 2020
- “Latest clinical data from the poliovirus trial in GBM”. 12th International Oncolytic Virus Conference . October 9, 2019 - October 12, 2019 2019
- “Virotherapy”. Meet the Expert Session – Local Therapies. 14th European Association of Neuro-Oncology (EANO) Meeting 2019 . September 19, 2019 - September 22, 2019 2019
- “Management of Recurrent Glioma: Update and Clinical Trials”. ASTRO-SNO Joint session. 2019 American Society for Radiation Oncology. September 16, 2019 - November 16, 2019 2019
- “Keynote Lecture: Intratumoral delivery of novel therapeutic approaches in primary gliomas: the polio story”. Annual Neurosurgery Forum. November 24, 2018 - November 24, 2018 2018
- “Recombiant poliovirus (PVSRIPO) in glioblastoma and others”. Viral and Gene Therapies: Break-Out Session. 22nd International Conference on Brain Tumor Research & Therapy. June 24, 2018 - June 27, 2018 2018
- “Determining the optimal dose for phase II/III studies of OV: The lesson of poliovirus”. Sunrise Session: Viral Therapy – Advances from Bench to Bedside . Society for Neuro-Oncology, 22nd Annual Meeting and Education Day. November 19, 2017 2017
- “Clinical Experience with Intratumoral Administration of Polio/Rhinovirus Chimera in GBM”. Society for Neuro-Oncology-Society for CNS Interstitial Delivery of Therapeutics Joint Conference on Therapeutic Delivery to the CNS. November 18, 2015 2015
- "PVSRIPO". Annual Conference of the Association of Science-Technology Centers (ASTC). October 17, 2015 2015
- “Oncolytic Viruses - Experience with Recombinant Poliovirus (PVSRIPO) in glioblastoma patients”. Immunotherapy and Cancer: Understanding the Challenges and Impact on the Clinical Trials Office. 7th Annual AACI Clinical Research Initiative Meeting. July 8, 2015 - July 8, 2015 2015
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.
